PT-141 (also written PT 141 or PT141) is the only FDA-approved compound that targets desire at the neurological level. Viagra and Cialis work on plumbing. PT-141 (bremelanotide, sold as Vyleesi) activates melanocortin-4 receptors in your brain to increase actual want. It's approved for women with low desire (HSDD), but the compounded version is used across genders. The mechanism doesn't care about your anatomy. It targets the same desire circuitry in everyone. The nausea at the full FDA dose (1.75mg) is significant, 40% in trials. Most people start at 500mcg and find their spot between there and 1mg. Takes about 45-60 minutes to kick in.
PT-141 Protocol
Dose: 500mcg-1.75mg per use | Frequency: As needed, at least 45 minutes before activity. Max 1 dose per 24 hours, max 8 doses per month (FDA guidance). | Cycle: As needed (not cycled) | Route: SubQ
Start at 500mcg, not the full FDA dose of 1.75mg. Most community users find their sweet spot between 500mcg and 1mg. The nausea at full dose is real. Lower doses often give the desired effect with far less GI distress. Takes 45-60 minutes to kick in.
PT-141 Effects
Increased sexual desire (65%). Works on the brain's desire circuitry, not mechanics. Users describe feeling genuinely interested rather than just physically responsive.
Enhanced arousal (58%). Both physical arousal and psychological arousal improve. That's the key differentiator from Viagra/Cialis.
Skin flushing / warmth (45%). A warm flush across the face and body within 30-60 minutes. Not a side effect for everyone. Some consider it part of the experience.
Improved satisfaction (50%). People in clinical trials said the overall experience was better, not just the physical part.
PT-141 Side Effects
Nausea (40%). The big trade-off. 40% at the full dose. Starting at 500mcg instead of 1.75mg cuts this dramatically.
Flushing (20%). Warm flush across your face, neck, and chest. Can be intense. Some people kind of like it, honestly.
Injection-site reactions (13%). Red mark or mild soreness where you pinned. Standard.
Headache (11%). Mild to moderate headache. Showed up in trials. Tends to pass.
Hyperpigmentation (1%). Rare but documented. Skin darkening on face, gums, or breasts. Usually goes back to normal when you stop.
PT-141 Dosing by Use Case
Condition
Dose
Duration
Notes
Low desire in women (HSDD)
500mcg-1.75mg as needed
As needed, max 8 doses/month
The FDA-approved indication (as Vyleesi). RECONNECT trials showed statistically significant improvement in desire and reduction in distress. Works best when the problem is desire, not physical response. If arousal mechanics are fine but you just don't want to, this is the target.
Psychogenic ED and low libido in men
500mcg-1mg as needed
As needed
Not FDA-approved for men, but widely used in compounded form. Targets desire and arousal at the brain level. Different mechanism than Viagra/Cialis (those handle blood flow). Works particularly well for stress-related or psychological ED where the plumbing works but the signal doesn't.
General libido enhancement
500mcg as needed
As needed, moderate frequency
For people who aren't clinically diagnosed but want more. Start low. 500mcg is usually enough for enhancement without the nausea of higher doses. Don't use more than 8 times per month. This isn't a daily supplement.
SSRI-related sexual dysfunction
500mcg-1mg as needed
As needed alongside SSRI
SSRIs suppress sexual desire and arousal. PT-141 works through a completely different pathway (melanocortin, not serotonin). Some users report it partially counteracts SSRI-induced sexual side effects. Not studied formally for this use.
PT-141 Results Timeline
Week 15-30 min, Warmth begins: Skin flush starts. Warmth across face, neck, chest. That's the melanocortin system waking up. Some people feel a subtle shift in mood or awareness.
Week 45-60 min, Desire shift: This is when the desire effect becomes noticeable. Things that wouldn't have registered now feel interesting. The mental shift is subtle but real. Not an overwhelming urge. More like the volume getting turned up.
Week 2-4 hours, Peak effect: Maximum desire and arousal window. Physical arousal response is heightened. Most people plan activity in this window. The effect works with you, not on you. It enhances desire that's already in the room. No lipstick for a pig here hon.
Week 6-8 hours, Gradual fade: Effect tapers. Some residual warmth or heightened awareness may linger. Nausea (if present) usually resolves within the first 2-3 hours. No crash or rebound.
Frequently Asked Questions About PT-141
What is PT-141?
PT-141 (bremelanotide) is a compound that activates melanocortin receptors in your brain to increase sexual desire. It's FDA-approved as Vyleesi for HSDD (hypoactive sexual desire disorder, the clinical way of saying 'I just never want to') in premenopausal women. The compounded version is used by both men and women. Unlike Viagra or Cialis, which work on blood flow, PT-141 targets the desire circuitry itself. It makes you want to, not just able to.
What is the best PT-141 dosage?
Start at 500mcg. The FDA dose is 1.75mg, but 40% of people at that dose get nauseous. Most community users find their sweet spot between 500mcg and 1mg. Inject subcutaneously in the abdomen or thigh at least 45 minutes before planned activity. Max one dose per 24 hours, max 8 doses per month. For a 10mg vial reconstituted with 2mL of bacteriostatic water, 500mcg is 10 units on a U-100 insulin syringe.
What are the side effects of PT-141?
Nausea (40% at full dose, much lower at 500mcg-1mg), skin flushing (20%), headache (11%), and injection-site reactions (13%). The nausea is the deal-breaker for most people. Starting at 500mcg instead of 1.75mg cuts it dramatically. Eating something 30-60 minutes before your dose helps. Rare but documented: temporary skin darkening (hyperpigmentation) on face, gums, or breasts. Usually reverses when you stop.
Does PT-141 work for men?
Yes, through the same brain mechanism. PT-141 activates the desire receptors in your brain (melanocortin-4). The signal works the same regardless of anatomy. It's not FDA-approved for men (the trials were in women), but it's widely used in compounded form for psychogenic ED and low libido. It works especially well when the problem is mental, not mechanical. If Viagra works for you physically but you have no desire, PT-141 targets the missing piece.
Does PT-141 work for women?
Yes. It's the only FDA-approved treatment that targets desire rather than arousal mechanics. The RECONNECT trials showed statistically significant improvement in sexual desire and reduction in distress in premenopausal women with HSDD. It doesn't work for everyone. In trials, responders reported a genuine shift in interest, not a forced feeling. It works best when the desire itself is what's missing, not physical response.
PT-141 nasal spray vs injection: which is better?
Injection is more predictable. PT-141 was originally tested as a nasal spray (Palatin Technologies' earlier formulation), but absorption through nasal membranes is inconsistent. You might get 70% of the dose one time and 40% the next. SubQ injection delivers the full dose reliably every time. The nasal spray is more convenient and painless, but you sacrifice dose precision. For first-timers figuring out their effective dose, injection makes more sense.
How long does PT-141 last?
The desire effect typically starts at 45-60 minutes, peaks at 2-4 hours, and fades over 6-8 hours. Some people report residual warmth or heightened awareness for up to 12 hours. The half-life is about 2.7 hours. One dose per 24 hours is the FDA guidance. Don't redose if the first one doesn't work strongly enough. Increase your dose next time instead.
How do you reconstitute PT-141?
Add 2mL of bacteriostatic water to a 10mg vial. That gives you 5mg per mL (5,000mcg per mL). For a 500mcg dose, draw 10 units on a U-100 insulin syringe. For 1mg, draw 20 units. For the full FDA dose of 1.75mg, draw 35 units. Aim the water at the glass wall, not directly onto the powder. Swirl gently. Never shake. Store in the fridge after reconstitution. Use within 4-6 weeks.
Evidence
Strong evidence. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Works through your brain's melanocortin receptors, the desire circuitry, not the plumbing. Fundamentally different from Viagra, which is about blood flow. The RECONNECT trials showed statistically significant improvement in sexual desire. Nausea is the main trade-off.
Approval status: FDA-approved (branded)
References
Diamond LE, Earle DC, Heiman JR, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med, 2006. PMID 16839319
Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol, 2019. PMID 31599840
Simon JA, Kingsberg SA, Portman D, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol, 2019. PMID 31599847
Mayer D, Lynch SE. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Ann Pharmacother, 2020. PMID 31893927
Koochaki P, Revicki DA, Wilson H, et al. The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results. J Womens Health (Larchmt), 2021. PMID 33538638
Simon JA, Kingsberg SA, Portman DJ, et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. J Womens Health (Larchmt), 2022. PMID 35230162
Safarinejad MR. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. J Sex Med, 2008. PMID 18331256
Storage
Lyophilized: Refrigerate at 2-8C. Stable for 12+ months sealed.
Reconstituted: Refrigerate. Use within 4-6 weeks.
Water: Bacteriostatic water, 2mL per 10mg vial.
Needle: 29-31 gauge, 0.5 inch for subcutaneous injection in abdomen or thigh
These statements have not been evaluated by the FDA. This content is for educational purposes only. Consult a healthcare professional before starting any protocol. vialprep sells injection supplies, not compounds.
